guaifenesin and Asthma studies

Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

Excerpt	Relevance	Reference
"This study evaluated substance P and neurokinin 1 protein expression and mucus content in endobronchial biopsy specimens from normal control subjects and asthmatic subjects."	9.09	Substance P and its receptor neurokinin 1 expression in asthmatic airways. ( Chu, HW; Kraft, M; Krause, JE; Martin, RJ; Rex, MD, 2000)
" azedarach fruit extract (MAE) using high-performance liquid chromatography (HPLC) and explored the therapeutic effects of MAE on pulmonary inflammation and mucus hypersecretion using a murine model of ovalbumin (OVA) exposed asthma."	8.84	Melia azedarach L. reduces pulmonary inflammation and mucus hypersecretion on a murine model of ovalbumin exposed asthma. ( Kim, T; Kim, WI; Lee, IS; Lee, SJ; Pak, SW; Shin, IS; Yang, YG, 2024)
"Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis."	8.78	Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991)
"In this study, we investigated whether 4-hydroxycinnamic acid (HA) has a palliative effect on asthmatic inflammatory responses using a mouse model of ovalbumin (OVA)-induced allergic asthma."	7.96	4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge. ( Choi, SJ; Kim, JC; Kim, MS; Kim, SH; Kim, YH; Ko, JW; Kwon, HJ; Seo, CS; Shin, IS; Shin, NR, 2020)
" In this study, we explored the suppressive effects of SAC on allergic airway inflammation induced in an ovalbumin (OVA)-induced asthma mouse model."	7.91	S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model. ( Kim, JC; Kim, JS; Kim, SH; Ko, JW; Kwon, HJ; Lee, IC; Shin, IS; Shin, NR, 2019)
"The purpose of this study is to explore the influence of ozone repeated short exposures on airway/lung inflammation, airway hyperresponsiveness (AHR) and airway hypersecretion in ovalbumin (OVA) sensitized/challenged asthmatic mouse model."	7.88	Effects of ozone repeated short exposures on the airway/lung inflammation, airway hyperresponsiveness and mucus production in a mouse model of ovalbumin-induced asthma. ( Bao, A; Bao, W; Fei, X; Zhang, M; Zhang, X; Zhang, Y; Zhou, X, 2018)
" This study aimed to evaluate the preventive activity of IMP in an ovalbumin (OVA)-induced murine model of asthma and to investigate its possible molecular mechanisms."	7.85	Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Kwon, HJ; Moon, OS; Park, HS; Seo, CS; Son, HY; Song, JW; Wijerathne, CUB; Won, YS, 2017)
" In the current study, an ovalbumin (OVA)‑induced allergic asthma model was used to investigate the immune‑modulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control)."	7.85	Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. ( Fu, AK; Fu, LQ; Hu, SL; Li, WF; Li, YL; Wang, YY; Wu, YP, 2017)
" argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma."	7.85	Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals. ( Jeong, SH; Kim, HJ; Kim, JC; Ko, JW; Park, SH; Ryu, HW; Shin, IS; Shin, NR; Yuk, HJ, 2017)
"Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation."	7.81	Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015)
"We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma."	7.81	Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015)
"We used ovalbumin (OVA)-based mouse models of asthma and primary CD4(+) T cells."	7.81	PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. ( Al-Ghareeb, K; Al-Khami, AA; Boulares, AH; El-Bahrawy, AH; Ghonim, MA; Ibba, SV; Lammi, MR; Mansy, MS; Naura, AS; Ochoa, A; Pyakurel, K; Rady, HF; Ramsay, A; Rodriguez, P; Wang, J, 2015)
"To explore the impact of ozone on the airway hyperresponsinveness (AHR), airway inflammation and mucus production in an allergic asthma mouse model."	7.81	[Effects of ozone oxidative stress on the airway hyperresponsiveness and mucus production in mice with acute allergic airway inflammation]. ( Aihua, B; Feng, L; Xin, Z; Yuqing, C; Zhang, M, 2015)
"The flavonoid naringenin has been shown to attenuate airway inflammation and airway hyper‑reactivity in acute murine models of asthma."	7.80	Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma. ( Gu, W; Mao, S; Shi, Y; Tan, Y, 2014)
" In this study, we evaluated the protective effects of EBM84 on asthmatic responses, particularly mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma."	7.79	EBM84 attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Ha, H; Jeon, WY; Lee, MY; Seo, CS; Shin, IS; Shin, NR, 2013)
"We investigated the suitability of dendritic polyglycerol sulfates (dPGS), conjugated with a hydrophilic version of the indocyanine green label with 6 sulfonate groups (6S-ICG) to monitor sites of inflammation using an experimental mouse model of allergic asthma."	7.79	Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. ( Alves, F; Biffi, S; Bosnjak, B; Dal Monego, S; Dullin, C; Epstein, MM; Garrovo, C; Licha, K; Welker, P, 2013)
" In this study, we intend to explore the role of PAR-1 in the process of thrombin-inducing transforming growth factor-β1 (TGF-β1) to promote airway remodeling in ovalbumin (OVA)-allergic rats."	7.79	Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats. ( Bi, M; Guo, A; Liu, Y; Lv, H; Pan, F; Qiu, L; Wang, P; Wang, Y; Yao, P; Zhang, N; Zhu, W, 2013)
"Montelukast, a leukotriene receptor antagonist, is used commercially as a maintenance treatment for asthma and to relieve allergic symptoms."	7.79	Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. ( Jeon, WY; Lee, MY; Shin, HK; Shin, IS, 2013)
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation."	7.78	Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012)
" Female BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation."	7.78	Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB. ( Cheng, C; Goh, FY; Guan, S; Leung, BP; Sethi, G; Shanmugam, MK; Upton, N; Wong, WS, 2012)
"Evidence suggests that nebulized lidocaine is beneficial in asthma therapy, but to what extent and the mechanisms underlying this effect remain poorly understood."	7.78	Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. ( Anjos-Valotta, EA; Arantes, AC; Cordeiro, RS; Cotias, AC; Couto, GC; Ferreira, TP; Jurgilas, PB; Martins, MA; Olsen, PC; Pão, CR; Pires, AL; Serra, MF; Silva, PM, 2012)
"Altered arginine metabolism, the uncoupling of nitric oxide synthase (NOS) by asymmetric dimethyl-arginine (ADMA), increased oxo-nitrosative stress, and cellular injury were reported in airway epithelial cells in asthma."	7.77	Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. ( Agrawal, A; Ahmad, T; Aich, J; Ghosh, B; Mabalirajan, U; Makhija, L; Sharma, A, 2011)
"The purposes of this study were to determine whether curcumin inhibits NF-κB-dependent transcription in vitro, and test whether treatment with curcumin reduces allergen-induced airway inflammation and hyper-responsiveness in a mouse model of asthma through inhibition of NF-κB pathway."	7.77	Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition. ( Cha, JY; Chang, BC; Jung, JE; Kim, DY; Kwon, HJ; Lee, BR; Oh, SW, 2011)
" This study aimed to evaluate the therapeutic availability of kefiran on the ovalbumin-induced asthma mouse model in which airway inflammation and airway hyper-responsiveness were found in the lung."	7.74	Inhibitory effect of kefiran on ovalbumin-induced lung inflammation in a murine model of asthma. ( Ahn, KS; Kim, MK; Kim, SY; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR; Park, BY, 2008)
"Sputum was collected from 12 asthmatics (26-73 year), lifelong non-smokers, at baseline, after eformoterol (24 mug) and after mannitol on each of four visits."	7.74	Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. ( Anderson, SD; Daviskas, E; Young, IH, 2007)
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma."	7.73	Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005)
"The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways."	7.73	Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006)
" As the lipoxygenase pathway is the only operant metabolic system available for arachidonic acid in the presence of aspirin and non-steroidal anti-inflammatory drugs--and as the nonsteroidal anti-inflammatory drugs themselves stimulate mucus production--it is possible that the mechanism responsible for mucus release in aspirin-sensitive asthmatics is the formation of these lipoxygenase products."	7.66	Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma. ( Kaliner, M; Marom, Z, 1983)
"Three patients suffering from severe, chronic, bronchial asthma underwent bronchoscopy and lavage, using in the irrigant fluid acetylcysteine, isoetharine and Solu-Medrol."	7.66	Status Asthmaticus: use of acetylcysteine during bronchoscopy and lavage to remove mucous plugs. ( Goldstein, IM; Goodman, AH; Millman, FM; Millman, M; Van Campen, SS, 1983)
"Allergic asthma is a chronic respiratory disease caused by an inappropriate immune response."	5.72	Gekko gecko extract attenuates airway inflammation and mucus hypersecretion in a murine model of ovalbumin-induced asthma. ( Kim, JS; Lee, JH; Lee, S; Moon, BC; Nam, HH; Noh, P; Ryu, SM; Seo, YS; Yang, S, 2022)
"Ovalbumin (OVA) was used as a stimulant to sensitize BALB/c mice to establish an asthmatic model."	5.62	Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin-Sensitized Asthmatic Mice. ( Chen, LC; Kuo, ML; Liu, MX; Ma, J; Shen, JJ, 2021)
"Cordycepin (Cor), which is a naturally occurring nucleoside derivative isolated from Cordyceps militaris, has been shown to exert excellent antiinflammatory activity in a murine model of acute lung injury."	5.42	Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. ( Deng, Y; He, Y; Li, T; Li, Y; Lin, R; Wang, W; Wei, J; Yang, X; Zhang, J, 2015)
"Melatonin was administered by intraperitoneal injection once per day at doses of 10 and 15 mg/kg from days 21 to 23 after the initial OVA sensitization."	5.40	Melatonin reduces airway inflammation in ovalbumin-induced asthma. ( Ahn, KS; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2014)
"Allantoin treatment led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5, in bronchoalveolar lavage (BAL) fluid."	5.36	Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. ( Jung, D; Kim, JH; Lee, H; Lee, JA; Lee, MY; Lee, NH; Seo, CS; Shin, HK, 2010)
"This study evaluated substance P and neurokinin 1 protein expression and mucus content in endobronchial biopsy specimens from normal control subjects and asthmatic subjects."	5.09	Substance P and its receptor neurokinin 1 expression in asthmatic airways. ( Chu, HW; Kraft, M; Krause, JE; Martin, RJ; Rex, MD, 2000)
"Ovalbumin (OVA) and BaP co-exposure were used to establish the aggravated asthma model."	4.84	Qufeng Xuanbi Formula inhibited benzo[a]pyrene-induced aggravated asthma airway mucus secretion by AhR/ROS/ERK pathway. ( Hu, J; Liu, CY; Liu, L; Shi, XL; Sun, XH; Tang, LL; Wang, BH; Wang, Y; Yang, Y; Yu, KY; Zhang, Q; Zhang, XN, 2024)
" azedarach fruit extract (MAE) using high-performance liquid chromatography (HPLC) and explored the therapeutic effects of MAE on pulmonary inflammation and mucus hypersecretion using a murine model of ovalbumin (OVA) exposed asthma."	4.84	Melia azedarach L. reduces pulmonary inflammation and mucus hypersecretion on a murine model of ovalbumin exposed asthma. ( Kim, T; Kim, WI; Lee, IS; Lee, SJ; Pak, SW; Shin, IS; Yang, YG, 2024)
"Azelastine (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-p hthalazinone hydrochloride), a novel long-acting antiasthmatic/antiallergic drug has been demonstrated to be effective in the treatment both of asthma and of allergic rhinitis."	4.78	Azelastine: a multifaceted drug for asthma therapy. ( Achterrath-Tuckermann, U; Minker, E; Paegelow, I; Schmidt, J; Szelenyi, I; Werner, H, 1991)
" It seems likely that this eicosanoid-mucus secretion relationship is very important in all forms of asthma, but most particularly in aspirin-related asthma."	4.77	The role of eicosanoids in respiratory mucus hypersecretion. ( Kaliner, MA; Lundgren, JD; Shelhamer, JH, 1985)
"Ovalbumin (OVA) and cold water-induced cold asthma model were established in male mice."	4.12	Processed product (Pinelliae Rhizoma Praeparatum) of Pinellia ternata (Thunb.) Breit. Alleviates the allergic airway inflammation of cold phlegm via regulation of PKC/EGFR/MAPK/PI3K-AKT signaling pathway. ( Chen, S; Cheng, Y; Li, J; Liu, H; Tao, X; Wang, C; Wang, H; Wu, H; Xia, J; Xie, Y; Yu, H; Zeng, P; Zhang, P; Zhang, X, 2022)
"We established ovalbumin (OVA) induced asthmatic murine model and orally administrated Iristectorigenin A at concentration of 5 and 10 mg/kg and dexamethasone as a positive control substance."	4.12	Iristectorigenin A exerts novel protective properties against airway inflammation and mucus hypersecretion in OVA-induced asthmatic mice: Iristectorigenin A ameliorates asthma phenotype. ( Abduwaki, M; Cui, J; Dong, JC; Luo, Q; Lv, Y; Nabijan, M; Nurahmat, M; Qin, J; Tang, W; Teng, F; Wang, S; Wei, Y; Wuniqiemu, T; Zhou, Y; Zhu, X, 2022)
" An ovalbumin (OVA)-induced mouse asthma model was established and the effect of acupuncture on airway hyperresponsiveness (AHR), mucus hypersecretion and inflammation was assessed."	4.02	TMT-based quantitative proteomics reveals suppression of SLC3A2 and ATP1A3 expression contributes to the inhibitory role of acupuncture on airway inflammation in an OVA-induced mouse asthma model. ( Cui, J; Dong, J; Dong, M; Qin, J; Tang, W; Teng, F; Wang, S; Wang, W; Wei, Y; Wuniqiemu, T; Zhu, X, 2021)
"In this study, we investigated whether 4-hydroxycinnamic acid (HA) has a palliative effect on asthmatic inflammatory responses using a mouse model of ovalbumin (OVA)-induced allergic asthma."	3.96	4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge. ( Choi, SJ; Kim, JC; Kim, MS; Kim, SH; Kim, YH; Ko, JW; Kwon, HJ; Seo, CS; Shin, IS; Shin, NR, 2020)
"Fifty rats (25 males and 25 females) were divided randomly into the control group, ovalbumin asthmatic model group, asthma low-, middle- and high-dose groups (n = 10, 5 males and 5 females each group)."	3.96	Effect of NF-κB signal pathway on mucus secretion induced by atmospheric PM ( Liu, Y; Peng, L; Wang, H; Zhang, B; Zhang, T; Zhou, L, 2020)
"In vivo, mice were sensitized and challenged by ovalbumin (OVA) to induce asthma."	3.96	Monocyte chemotactic protein-inducing protein 1 negatively regulating asthmatic airway inflammation and mucus hypersecretion involving γ-aminobutyric acid type A receptor signaling pathway in vivo and in vitro. ( Chen, ZH; Dai, GM; Deng, HJ; Mao, RL; Ran, YJ; Wang, JJ; Zhu, T, 2020)
" In this study, we explored the suppressive effects of SAC on allergic airway inflammation induced in an ovalbumin (OVA)-induced asthma mouse model."	3.91	S-Allyl cysteine reduces eosinophilic airway inflammation and mucus overproduction on ovalbumin-induced allergic asthma model. ( Kim, JC; Kim, JS; Kim, SH; Ko, JW; Kwon, HJ; Lee, IC; Shin, IS; Shin, NR, 2019)
"The purpose of this study is to explore the influence of ozone repeated short exposures on airway/lung inflammation, airway hyperresponsiveness (AHR) and airway hypersecretion in ovalbumin (OVA) sensitized/challenged asthmatic mouse model."	3.88	Effects of ozone repeated short exposures on the airway/lung inflammation, airway hyperresponsiveness and mucus production in a mouse model of ovalbumin-induced asthma. ( Bao, A; Bao, W; Fei, X; Zhang, M; Zhang, X; Zhang, Y; Zhou, X, 2018)
"NK may be an effective alternative therapeutic option in patients with CRSwNP and comorbid asthma by causing fibrin degradation."	3.85	Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus. ( Fujieda, S; Imoto, Y; Ishizuka, T; Kato, Y; Narita, N; Sakashita, M; Takabayashi, T; Tokunaga, T; Yoshida, K, 2017)
" This study aimed to evaluate the preventive activity of IMP in an ovalbumin (OVA)-induced murine model of asthma and to investigate its possible molecular mechanisms."	3.85	Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Kwon, HJ; Moon, OS; Park, HS; Seo, CS; Son, HY; Song, JW; Wijerathne, CUB; Won, YS, 2017)
" This study evaluates whether intranasally delivered gas-filled microbubble (MB)-associated ovalbumin (OVA), used as a model allergen, can serve as a therapeutic treatment in a mouse model of established allergic asthma."	3.85	Therapeutic intranasal instillation of allergen-loaded microbubbles suppresses experimental allergic asthma in mice. ( Bioley, G; Corthésy, B, 2017)
" In the current study, an ovalbumin (OVA)‑induced allergic asthma model was used to investigate the immune‑modulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control)."	3.85	Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. ( Fu, AK; Fu, LQ; Hu, SL; Li, WF; Li, YL; Wang, YY; Wu, YP, 2017)
" argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma."	3.85	Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals. ( Jeong, SH; Kim, HJ; Kim, JC; Ko, JW; Park, SH; Ryu, HW; Shin, IS; Shin, NR; Yuk, HJ, 2017)
"We sought to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of asthma."	3.85	Pentraxin 3 deletion aggravates allergic inflammation through a T ( Almiski, MS; Balhara, J; Doeing, D; Gounni, AS; Halayko, AJ; Matzuk, MM; McConville, J; Muhuri, A; Shan, L; Zhang, J, 2017)
" PRE treatment decreased mucus production in airway epithelium, inflammatory cell number, eosinophilia, type 2 cytokines, and histamine in bronchoalveolar lavage fluid (BALF)."	3.85	Reduced allergic lung inflammation by root extracts from two species of Peucedanum through inhibition of Th2 cell activation. ( Chun, JM; Gu, GJ; Kim, HS; Kwon, BI; Lee, AR; Lee, AY, 2017)
" In addition, to investigate the effects of CuONPs on asthma development, we used a murine model of ovalbumin (OVA)-induced asthma."	3.83	Copper oxide nanoparticles aggravate airway inflammation and mucus production in asthmatic mice via MAPK signaling. ( Ahn, KS; Jeon, CM; Kim, JC; Ko, JW; Kwon, OK; Lee, IC; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2016)
" This study aimed to determine the possible effects and underlying mechanisms of Suhuang on chronic ovalbumin (OVA)-induced airway hyperresponsiveness (AHR), inflammation, and remodeling in mice."	3.83	Suhuang antitussive capsule at lower doses attenuates airway hyperresponsiveness, inflammation, and remodeling in a murine model of chronic asthma. ( Che, LQ; Chen, ZH; Lai, TW; Li, W; Shen, HH; Wang, HS; Wu, YF; Xiao, H; Ying, SM; Zhang, C; Zhang, LH, 2016)
"Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation."	3.81	Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation. ( Ding, PS; Fang, L; He, F; Liu, RY; Shen, QY; Wu, HM, 2015)
"We have reported that triptolide inhibited pulmonary inflammation in patients with steroid-resistant asthma."	3.81	Triptolide suppresses airway goblet cell hyperplasia and Muc5ac expression via NF-κB in a murine model of asthma. ( Chen, M; Huang, L; Jiang, S; Liang, R; Lin, X; Lv, Z; Shi, J; Zhang, W, 2015)
"We used ovalbumin (OVA)-based mouse models of asthma and primary CD4(+) T cells."	3.81	PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. ( Al-Ghareeb, K; Al-Khami, AA; Boulares, AH; El-Bahrawy, AH; Ghonim, MA; Ibba, SV; Lammi, MR; Mansy, MS; Naura, AS; Ochoa, A; Pyakurel, K; Rady, HF; Ramsay, A; Rodriguez, P; Wang, J, 2015)
"To explore the impact of ozone on the airway hyperresponsinveness (AHR), airway inflammation and mucus production in an allergic asthma mouse model."	3.81	[Effects of ozone oxidative stress on the airway hyperresponsiveness and mucus production in mice with acute allergic airway inflammation]. ( Aihua, B; Feng, L; Xin, Z; Yuqing, C; Zhang, M, 2015)
"The flavonoid naringenin has been shown to attenuate airway inflammation and airway hyper‑reactivity in acute murine models of asthma."	3.80	Naringenin inhibits allergen‑induced airway remodeling in a murine model of asthma. ( Gu, W; Mao, S; Shi, Y; Tan, Y, 2014)
" In this study, we investigated the protective effects of SG extract on allergic asthma in an ovalbumin (OVA)-induced asthma murine model and lipopolysaccharide (LPS)-stimulated RAW264."	3.80	Siegesbeckia glabrescens attenuates allergic airway inflammation in LPS-stimulated RAW 264.7 cells and OVA induced asthma murine model. ( Ahn, KS; Hong, JM; Jeon, CM; Kim, HS; Kwon, OK; Myung, PK; Oh, SR; Shin, IS; Shin, NR, 2014)
" In this study, we evaluated the protective effects of EBM84 on asthmatic responses, particularly mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma."	3.79	EBM84 attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma. ( Ha, H; Jeon, WY; Lee, MY; Seo, CS; Shin, IS; Shin, NR, 2013)
"We investigated the suitability of dendritic polyglycerol sulfates (dPGS), conjugated with a hydrophilic version of the indocyanine green label with 6 sulfonate groups (6S-ICG) to monitor sites of inflammation using an experimental mouse model of allergic asthma."	3.79	Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. ( Alves, F; Biffi, S; Bosnjak, B; Dal Monego, S; Dullin, C; Epstein, MM; Garrovo, C; Licha, K; Welker, P, 2013)
"In the OVA-exposed mice for 6 wks inflammatory cells infiltration, levels of inflammatory cytokines and chemokines, goblet cell metaplasia, collagen deposition and AHR were significantly decreased by treatment with AR inhibitor, fidarestat."	3.79	Aldose reductase inhibition prevents allergic airway remodeling through PI3K/AKT/GSK3β pathway in mice. ( Aguilera-Aguirre, L; Boldogh, I; Boulares, HA; Calhoun, WJ; Naura, AS; Ramana, KV; Srivastava, SK; Yadav, UC, 2013)
" In this study, we intend to explore the role of PAR-1 in the process of thrombin-inducing transforming growth factor-β1 (TGF-β1) to promote airway remodeling in ovalbumin (OVA)-allergic rats."	3.79	Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats. ( Bi, M; Guo, A; Liu, Y; Lv, H; Pan, F; Qiu, L; Wang, P; Wang, Y; Yao, P; Zhang, N; Zhu, W, 2013)
"Montelukast, a leukotriene receptor antagonist, is used commercially as a maintenance treatment for asthma and to relieve allergic symptoms."	3.79	Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. ( Jeon, WY; Lee, MY; Shin, HK; Shin, IS, 2013)
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation."	3.78	Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012)
" Female BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation."	3.78	Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB. ( Cheng, C; Goh, FY; Guan, S; Leung, BP; Sethi, G; Shanmugam, MK; Upton, N; Wong, WS, 2012)
"Evidence suggests that nebulized lidocaine is beneficial in asthma therapy, but to what extent and the mechanisms underlying this effect remain poorly understood."	3.78	Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. ( Anjos-Valotta, EA; Arantes, AC; Cordeiro, RS; Cotias, AC; Couto, GC; Ferreira, TP; Jurgilas, PB; Martins, MA; Olsen, PC; Pão, CR; Pires, AL; Serra, MF; Silva, PM, 2012)
"Altered arginine metabolism, the uncoupling of nitric oxide synthase (NOS) by asymmetric dimethyl-arginine (ADMA), increased oxo-nitrosative stress, and cellular injury were reported in airway epithelial cells in asthma."	3.77	Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. ( Agrawal, A; Ahmad, T; Aich, J; Ghosh, B; Mabalirajan, U; Makhija, L; Sharma, A, 2011)
"In the present study, we investigated whether the Lagerstroemia indica Linn (LI) extract has an anti-inflammatory effect on lung inflammation in ovalbumin-induced asthmatic mice."	3.77	Anti-inflammatory effects of ethanolic extract from Lagerstroemia indica on airway inflammation in mice. ( Kim, DH; Kim, IS; Lee, JS; Song, BB; Yang, EJ; Yun, CY, 2011)
"The purposes of this study were to determine whether curcumin inhibits NF-κB-dependent transcription in vitro, and test whether treatment with curcumin reduces allergen-induced airway inflammation and hyper-responsiveness in a mouse model of asthma through inhibition of NF-κB pathway."	3.77	Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition. ( Cha, JY; Chang, BC; Jung, JE; Kim, DY; Kwon, HJ; Lee, BR; Oh, SW, 2011)
" Becker (VM) ethanolic (EtOH) extract in the treatment of bronchial asthma in an ovalbumin (OVA)-induced asthmatic BALB/c mouse model."	3.76	Anti-inflammatory and anti-asthmatic effects of Viola mandshurica W. Becker (VM) ethanolic (EtOH) extract on airway inflammation in a mouse model of allergic asthma. ( Ahn, KS; Kim, HS; Kwon, OK; Lee, HK; Lee, MY; Oh, SR; Yuk, JE, 2010)
"The effect of PET was investigated in ovalbumin (OVA) immunized BALB/c mice given intranasally together with antigen challenge in the murine model of allergic airway disease (asthma) with the analysis of the inflammatory and immune parameters in the lung."	3.76	Petasites extract Ze 339 (PET) inhibits allergen-induced Th2 responses, airway inflammation and airway hyperreactivity in mice. ( Brattström, A; Maillet, I; Moser, R; Ryffel, B; Schapowal, A; Schnyder, B, 2010)
" The data showed that chronic SJ infection suppressed airway eosinophilia, mucus production and antigen-specific IgE responses induced by ovalbumin (OVA) sensitization and challenge."	3.76	Helminth infection inhibits airway allergic reaction and dendritic cells are involved in the modulation process. ( An, G; Gao, W; Ji, W; Li, J; Liu, P; Liu, X; Shen, Y; Wang, S; Wu, Z; Yang, X; Zhu, Y, 2010)
"ITE obtained from leaves by supercritical carbon dioxide extraction was investigated in ovalbumin (OVA) immunised BALB/c mice given intranasally together with antigen challenge in the murine model of allergic airway disease (asthma) with the analysis of the inflammatory and immune parameters in the lung."	3.76	The plant extract Isatis tinctoria L. extract (ITE) inhibits allergen-induced airway inflammation and hyperreactivity in mice. ( Brattström, A; Kamal, MA; Maillet, I; Moser, R; Ryffel, B; Schapowal, A, 2010)
"Theophylline can increase the transepithelial secretion of fluid into the respiratory tract lumen by stimulating the chloride pump which is controlled by cyclic AMP."	3.76	Theophylline and mucociliary clearance. ( Ziment, I, 1987)
") inhibited the number of coughs induced by capsaicin aerosol (P<0."	3.74	Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. ( Kuraya, T; Morimoto, K; Nosaka, E; Takahashi, S; Tsuchida, H; Yamashita, M, 2008)
" This study aimed to evaluate the therapeutic availability of kefiran on the ovalbumin-induced asthma mouse model in which airway inflammation and airway hyper-responsiveness were found in the lung."	3.74	Inhibitory effect of kefiran on ovalbumin-induced lung inflammation in a murine model of asthma. ( Ahn, KS; Kim, MK; Kim, SY; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR; Park, BY, 2008)
" The expression of GAD in the cytosol and GABAARs in the apical membranes of airway epithelial cells increased markedly when mice were sensitized and then challenged with ovalbumin, an approach for inducing allergic asthmatic reactions."	3.74	A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. ( Fan, Y; Hirota, JA; Inman, MD; Ju, W; Kelly, MM; Li, J; Liu, M; Lu, WY; O'Byrne, PM; Orser, B; Wang, S; Xiang, YY; Yang, X; Ye, B, 2007)
" In order to investigate the pharmacological effects of kefir, we used a mouse asthma model, in which airway inflammation and airway remodeling was produced by ovalbumin sensitization and challenge."	3.74	Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model. ( Ahn, KS; Kim, MJ; Kim, MK; Kwon, OK; Lee, HK; Lee, IY; Lee, MY; Oh, SR, 2007)
"Sputum was collected from 12 asthmatics (26-73 year), lifelong non-smokers, at baseline, after eformoterol (24 mug) and after mannitol on each of four visits."	3.74	Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. ( Anderson, SD; Daviskas, E; Young, IH, 2007)
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma."	3.73	Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005)
"The effects of niflumic acid (NA), a relatively specific blocker of calcium-activated chloride channel (CLCA), on goblet cell hyperplasia, eosinophil accumulation, and airway hyperresponsiveness were evaluated after IL-13 instillation into the airways."	3.73	Niflumic acid suppresses interleukin-13-induced asthma phenotypes. ( Aizawa, H; Fukuyama, S; Inoue, H; Matsumoto, K; Matsumoto, T; Matsumura, M; Nakanishi, Y; Nakano, T; Tsuda, M, 2006)
"An asthma model was sensitized and challenged by ovalbumin (OVA) in male C57BL/6 mice."	3.73	CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma. ( Shen, HH; Wang, SB; Xu, F; Xu, WH; Zhang, GS, 2006)
"Twenty-four BALB/c mice were randomly divided into 3 equal groups: asthma group [ovalbumin (OVA) and aluminum hydroxide were injected intraperitoneally on day 0 and day 14 so as to establish mouse asthma model and aerosol inhalation of OVA PBS was conducted for 30 min on the days 21, 22, and 24], asthma + dexamethasone group (OVA and aluminum hydroxide were injected intraperitoneally on days 0 and 14, aerosol inhalation of OVA PBS was conducted for 30 min on the days 21, 22, and 24, and dexamethasone was injected intraperitoneally 1 hour before the aerosol inhalation), and control group (aerosol inhalation of PBS was conducted instead)."	3.73	[Effects of glucocorticoid on airway mucus secretion in asthma: experiment with asthmatic mouse model]. ( Liu, JB; Xing, LH; Xu, YJ; Zhang, HL; Zhang, ZX, 2006)
" To clarify the effects of DE on the exacerbation of asthma, guinea pigs were exposed 12 h daily to 3 mg/m(3) DE or air for 8 wk with or without sensitization to ovalbumin (OVA)."	3.71	Exposure to diesel exhaust exacerbates allergen-induced airway responses in guinea pigs. ( Hashimoto, K; Hirano, K; Ishii, Y; Kimura, T; Masuyama, K; Morishima, Y; Nomura, A; Sagai, M; Sakamoto, T; Sekizawa, K; Takano, H; Uchida, Y, 2001)
" To elucidate whether heparin affects goblet cell secretion in asthmatic airways and, if so, what the mechanism of action is, we studied guinea pigs sensitized with ovalbumin (OVA) by determining the mucus score (MS) of tracheal goblet cells stained with Alcian blue and PAS."	3.70	[Effect of heparin on airway goblet cell secretion in sensitized guinea pigs]. ( Kondo, M; Nagai, A; Nakata, J; Takeda, Y; Takeyama, K; Tamaoki, J; Yamawaki, I, 1998)
"The ovalbumin-sensitized guinea pig is commonly used as a small animal model of allergic asthma."	3.69	Effect of dexamethasone on antigen-induced high molecular weight glycoconjugate secretion in allergic guinea pigs. ( Boulet, L; Chan, CC; Plant, M; Pon, DJ; Rodger, IW; Savoie, C; van Staden, CJ; Zwikker, M, 1995)
"To determine whether markers of mucus secretion can be quantified in airway lining fluid from asthmatic and from healthy subjects, we measured levels of a mucin-like glycoprotein (MLG) and lactoferrin in sputum induced by inhalation of hypertonic (3%) saline in 18 asthmatic and in 10 healthy subjects."	3.68	Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. ( Basbaum, CB; Boushey, HA; Fahy, JV; Finkbeiner, WE; Liu, J; Steiger, DJ, 1993)
"Nasal mucociliary clearance was measured using a saccharin technique in 172 patients with perennial rhinitis (76 also had asthma) and in 121 patients with chronic infected rhinosinusitis (40 had asthma, 35 had bronchiectasis)."	3.67	Abnormal nasal mucociliary clearance in patients with rhinitis and its relationship to concomitant chest disease. ( Cole, PJ; Greenstone, MA; Mackay, IS; Stanley, PJ; Wilson, R, 1985)
" As the lipoxygenase pathway is the only operant metabolic system available for arachidonic acid in the presence of aspirin and non-steroidal anti-inflammatory drugs--and as the nonsteroidal anti-inflammatory drugs themselves stimulate mucus production--it is possible that the mechanism responsible for mucus release in aspirin-sensitive asthmatics is the formation of these lipoxygenase products."	3.66	Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma. ( Kaliner, M; Marom, Z, 1983)
"Three patients suffering from severe, chronic, bronchial asthma underwent bronchoscopy and lavage, using in the irrigant fluid acetylcysteine, isoetharine and Solu-Medrol."	3.66	Status Asthmaticus: use of acetylcysteine during bronchoscopy and lavage to remove mucous plugs. ( Goldstein, IM; Goodman, AH; Millman, FM; Millman, M; Van Campen, SS, 1983)
"A 14-year-old boy with severe asthma was treated with prednisone and disodium cromoglycate with considerable subjective improvement, though there was persistent airways obstruction."	3.65	Sudden death in a young asthmatic. ( Batten, J; Gregg, I, 1969)
"Neutrophilic inflammation is believed to contribute to the airway obstruction and remodelling in equine asthma."	2.90	Randomised study of the immunomodulatory effects of azithromycin in severely asthmatic horses. ( Bédard, C; Hélie, P; Labrecque, O; Lavoie, JP; Mainguy-Seers, S; Vargas, A, 2019)
"Among these, COPD is more prominent worldwide."	2.82	Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. ( Kumar, G; Pathak, K; Sharma, A; Virmani, R; Virmani, T, 2022)
"Chronic cough is a common problem of various etiologies."	2.79	The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: descriptive, prospective, clinical trial. ( Asilsoy, S; Durmaz, C; Usta Guc, B, 2014)
"Allergic bronchial asthma is a chronic disease of the airways that is characterized by symptoms like respiratory distress, chest tightness, wheezing, productive cough, and acute episodes of broncho-obstruction."	2.66	More Than Just a Barrier: The Immune Functions of the Airway Epithelium in Asthma Pathogenesis. ( Ehlers, JC; Frey, A; Lunding, LP; Weckmann, M; Wegmann, M; Zissler, UM, 2020)
"Asthma, chronic obstructive pulmonary disease, and cystic fibrosis are three chronic pulmonary diseases that affect an estimated 420 million individuals across the globe."	2.58	Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases. ( Breitzig, MT; Kolliputi, N; Lockey, RF; Saco, TV, 2018)
"In asthma and chronic obstructive pulmonary disease (COPD), airway mucus hypersecretion contributes to impaired mucociliary clearance, mucostasis and, potentially, the development of mucus plugging of the airways."	2.53	Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases. ( Ha, EV; Rogers, DF, 2016)
"The hallmark traits of chronic obstructive airway diseases are inflammation, airway constriction due to hyperreactivity and mucus overproduction."	2.52	CLCA1 and TMEM16A: the link towards a potential cure for airway diseases. ( Brett, TJ, 2015)
"The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes"."	2.48	Clinical phenotypes of COPD: identification, definition and implications for guidelines. ( Calle, M; Miravitlles, M; Soler-Cataluña, JJ, 2012)
"Although cough is one of the defining symptoms of asthma, wheeze, chest tightness and breathlessness have generally received more attention."	2.46	Interrupting the cough reflex in asthma. ( Smith, JA, 2010)
"Chronic bronchitis is characterized by mucus hypersecretion."	2.37	The pathology of obstructive and inflammatory airway diseases. ( Reid, LM, 1986)
"Occasionally, segmental or subsegmental atelectasis develops, but in most series radiographically visible atelectasis is uncommon."	2.37	Clinical aspects of mucus and mucous plugging in asthma. ( Fanta, CH, 1985)
"IL-13 develops bronchial asthma by elevating bronchial hyperresponsiveness and enables production of immunoglobulin M (IgM) and IgE."	1.72	High throughput virtual screening strategy to develop a potential treatment for bronchial asthma by targeting interleukin 13 cytokine signaling. ( Jing, J; Ma, Q; Tong, H, 2022)
"Allergic asthma is a chronic respiratory disease caused by an inappropriate immune response."	1.72	Gekko gecko extract attenuates airway inflammation and mucus hypersecretion in a murine model of ovalbumin-induced asthma. ( Kim, JS; Lee, JH; Lee, S; Moon, BC; Nam, HH; Noh, P; Ryu, SM; Seo, YS; Yang, S, 2022)
"Ovalbumin (OVA) was used as a stimulant to sensitize BALB/c mice to establish an asthmatic model."	1.62	Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin-Sensitized Asthmatic Mice. ( Chen, LC; Kuo, ML; Liu, MX; Ma, J; Shen, JJ, 2021)
"Tectochrysin treatment reduced the level of IgE in plasma, the percentage of eosinophils in total white blood cells in peripheral blood, the total number of cells in BAL fluid, and eosinophil peroxidase activity in lung tissues."	1.62	Tectochrysin ameliorates murine allergic airway inflammation by suppressing Th2 response and oxidative stress. ( Fang, L; He, Z; Jiang, X; Wu, F; Xu, Z; Yan, Y; Yu, D; Yuan, X; Zhang, T; Zhou, S, 2021)
"The percentages of airway obstruction due to mucus plugs were notably higher in the fourth- and fifth-generation bronchi (17."	1.56	Changes in airway diameter and mucus plugs in patients with asthma exacerbation. ( Kurashima, K; Nakamoto, Y; Takaku, Y; Takayanagi, N; Takizawa, H; Yanagisawa, T; Yoshida, Y, 2020)
"Dithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities."	1.51	An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. ( Boucher, RC; Delion, MF; Donaldson, SH; Ehre, C; Esther, CR; Fontana, NC; Grubb, BR; Hill, DB; Hothem, LN; Kato, T; Livraghi-Butrico, A; Markovetz, MR; Morrison, CB; Rushton, ZL; Thelin, WR; Villalon, D; Wang, B, 2019)
"Pneumocystis associates to more severe Chronic Obstructive Pulmonary Disease (COPD), asthma, respiratory distress of premature newborns, and is a consistent subclinical infection between 2 and 5 months of age when hospitalizations for respiratory cause and infant mortality are higher."	1.51	Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection. ( Bórquez, P; Bustamante, R; Gallo, M; Iturra, PA; Méndez, A; Ponce, CA; Rojas, DA; Vargas, SL, 2019)
"Mucus plugs are a plausible mechanism of chronic airflow obstruction in severe asthma, and EPO-generated oxidants may mediate mucus plug formation."	1.48	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. ( Bleecker, ER; Castro, M; Di Maio, S; Dunican, EM; Elicker, BM; Erzurum, SC; Fahy, JV; Fain, SB; Gierada, DS; Gordon, ED; Hoffman, EA; Israel, E; Jarjour, NN; Lachowicz-Scroggins, ME; Levy, BD; Mauger, DT; Meyers, DA; Nagle, SK; Newell, JD; Peters, MC; Phillips, BR; Raymond, WW; Schiebler, ML; Wenzel, SE; Woodruff, PG, 2018)
"Daily cough was recorded in 28."	1.48	Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations. ( Crespo, A; García-Rivero, JL; López-Viña, A; Marina-Malanda, N; Martínez-Rivera, C; Mayoralas-Alises, S; Padilla, A; Pallarés-Sanmartín, A; Pascual-Erquicia, S; Picado, C; Pinedo-Sierra, C; Plaza, V, 2018)
"Casticin is an active compound that possesses broad biological activities including anti-inflammatory effect."	1.48	Casticin alleviates lipopolysaccharide-induced inflammatory responses and expression of mucus and extracellular matrix in human airway epithelial cells through Nrf2/Keap1 and NF-κB pathways. ( Wang, J, 2018)
"TAS2R agonists attenuated features of airway remodeling including smooth muscle mass, extracellular matrix deposition and pro-fibrotic signaling, and also prevented mucus accumulation and development of AHR in mice."	1.46	Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice. ( Deshpande, DA; Knight, MJ; Nayak, AP; Oliver, B; Pan, S; Sharma, P; Tang, F; Wang, N; Yi, R, 2017)
"①In 2014, the acute attacks of bronchial asthma were (1."	1.46	[Clinical therapeutic effect on bronchial asthma in children of different body constitutions treated with ( Deng, Y; Shi, Y; Tang, M; Wang, P; Yang, H; Zhang, L, 2017)
"Mice lacking the endogenous β2-adrenoceptor (β2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of β2AR agonists to PNMT-KO mice restores the phenotype."	1.43	Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. ( Al-Sawalha, N; Bond, RA; Forkuo, GS; Gonnella, PA; Joshi, R; Kim, H; Knoll, BJ; Parra, S; Penn, RB; Pera, T; Thanawala, VJ; Valdez, D; Walker, JK, 2016)
"Cordycepin (Cor), which is a naturally occurring nucleoside derivative isolated from Cordyceps militaris, has been shown to exert excellent antiinflammatory activity in a murine model of acute lung injury."	1.42	Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. ( Deng, Y; He, Y; Li, T; Li, Y; Lin, R; Wang, W; Wei, J; Yang, X; Zhang, J, 2015)
"We used a murine model of respiratory allergy to the mite Blomia tropicalis (Bt) and evaluated certain parameters known to be altered in this model."	1.42	The anti-allergic activity of Cymbopogon citratus is mediated via inhibition of nuclear factor kappa B (Nf-Κb) activation. ( Alcântara-Neves, NM; Alves de Souza, S; da Silva Velozo, E; Ferreira Silva, HB; Figueiredo, CA; Meneses Souza, FL; Pires de Oliveira, A; Pontes-de-Carvalho, LC; Rios, R; Santos Alves, W; Santos Costa, R; Santos Serafim Machado, M; Sarmento Silva, TM; Silva, ML; Vilany Queiroz Carneiro, N, 2015)
"Sesamin is a natural polyphenolic compound with strong anti-oxidative effects."	1.40	Protective effects of the polyphenol sesamin on allergen-induced T(H)2 responses and airway inflammation in mice. ( Kao, ST; Lee, CC; Lin, CH; Shen, ML; Wu, DC; Zhou, N, 2014)
"Melatonin was administered by intraperitoneal injection once per day at doses of 10 and 15 mg/kg from days 21 to 23 after the initial OVA sensitization."	1.40	Melatonin reduces airway inflammation in ovalbumin-induced asthma. ( Ahn, KS; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2014)
"Additionally, acute respiratory infections did not affect the microbiological colonization in asthmatics' airways (P = 0."	1.40	No direct association between asthma and the microbiome based on currently available techniques. ( Yayan, J, 2014)
"Inflammation was assessed by the total and differential cell counts and IL-4 and IL-5 levels in bronchoalveolar lavage (BAL) fluid."	1.38	The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma. ( Daubeuf, F; Frossard, N; Nemska, S; Reber, LL, 2012)
"Allantoin treatment led to significant reduction in the levels of Ig(immunoglobulin)E and T-helper-2-type cytokines, such as IL(interleukin)-4 and IL-5, in bronchoalveolar lavage (BAL) fluid."	1.36	Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. ( Jung, D; Kim, JH; Lee, H; Lee, JA; Lee, MY; Lee, NH; Seo, CS; Shin, HK, 2010)
" Smoking and asthma were risk factors for CMH, with a dose-response effect of tobacco consumption, and smoking habits also predicting incidence of CMH."	1.36	Chronic mucus hypersecretion: prevalence and risk factors in younger individuals. ( Backer, V; Harmsen, L; Ingebrigtsen, T; Kyvik, KO; Skadhauge, LR; Steffensen, IE; Thomsen, SF, 2010)
"In both asthma and COPD mouse models, pendrin was up-regulated at the apical side of airway epithelial cells in association with mucus overproduction."	1.35	Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. ( Aizawa, H; Arima, K; Fukuda, T; Green, ED; Hasegawa, M; Hayashi, H; Hoshino, T; Inoue, H; Inoue, M; Izuhara, K; Kanaji, S; Kubo, H; Matsushita, H; Nagai, H; Nakao, I; Nakayama, K; Ohta, S; Okinami, S; Sagara, H; Shiraki, A; Sugiyama, K; Suzuki, K; Tanaka, H; Toda, S; Watanabe, M; Yamaya, M; Yuyama, N, 2008)
"To evaluate lung inflammation, mucus metaplasia and AHR in relationship with age in murine models of allergic asthma comparing young and older mice."	1.34	Effect of ageing on pulmonary inflammation, airway hyperresponsiveness and T and B cell responses in antigen-sensitized and -challenged mice. ( Busse, PJ; Li, XM; Schofield, B; Srivastava, K; Zhang, TF, 2007)
"Guaifenesin is a commonly used expectorant whose use may lead to the occasional formation of guaifenesin urinary stones."	1.33	Spontaneous dissolution of a guaifenesin stone. ( Fallon, B; Nguyen, TT; Winfield, HN, 2005)
" Inhalation of aerosolized p38alpha-ASO using an aerosol chamber dosing system produced measurable lung deposition of ASO and significant reduction of ovalbumin (OVA-)-induced increases in total cells, eosinophils, and interleukin 4 (IL-4), IL-5, and IL-13 levels in bronchoalveolar lavage fluid, and dose-dependent inhibition of airway hyperresponsiveness in allergen-challenged mice."	1.33	Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. ( Chan, JH; Choo, HH; Crosby, JR; Duan, W; Karras, JG; Leung, BP; McKay, K; Wong, WS, 2005)
" In the present study, we have investigated the effect of a therapeutic dosing regimen with an anti-IL-13 monoclonal antibody (mAb) in a chronic mouse model of persistent asthma."	1.33	Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. ( Bugelski, PJ; Das, AM; Emmell, E; Giles-Komar, J; Griswold, DE; Lakshminarayanan, M; Li, L; Petley, T; Rafferty, P; Volk, A; Yang, G, 2005)
"Treatment was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation and hyper-reactivity."	1.33	Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling. ( Lloyd, CM; McMillan, SJ; Xanthou, G, 2005)
"Based on time from onset of symptoms to death, cases fell into two distinct groups: short course <3 (1."	1.33	Time to death, airway wall inflammation and remodelling in fatal asthma. ( Abramson, MJ; Elliot, JG; James, AL; Walters, EH, 2005)
"Airway eosinophilia was observed during both responses."	1.33	Effect of disodium cromoglycate on airway mucus secretion during antigen-induced late asthmatic responses in a murine model of asthma. ( Arakawa, H; Koyama, H; Mayuzumi, H; Mizuno, T; Mochizuki, H; Morikawa, A; Nishimura, H; Ohki, Y; Tokuyama, K, 2005)
"Human bronchial asthma is characterized by airway hyperresponsiveness (AHR), eosinophilic airway inflammation, mucus hypersecretion and high serum level of IgE."	1.33	Contribution of IL-18-induced innate T cell activation to airway inflammation with mucus hypersecretion and airway hyperresponsiveness. ( Ishikawa, Y; Nakanishi, K; Yoshimoto, T, 2006)
"This is the first evidence that autoimmune diabetes-prone NOD mice can also give rise to enhanced Th2-mediated responses and might thus provide a useful model for the study of common genetic and cellular components, including NKT cells that contribute to both asthma and type 1 diabetes."	1.32	Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. ( Araujo, LM; Bach, JF; Diem, S; Dy, M; Herbelin, A; Lefort, J; Leite-de-Moraes, MC; Nahori, MA; Vargaftig, BB; Zhu, R, 2004)
"One hundred and two COPD patients and 183 controls, together with 46 asthma patients and 48 patients with chronic mucous hypersecretion (CMH) were examined."	1.32	Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland. ( Andrason, H; Gislason, T; Gulcher, JR; Hakonarson, H; Halapi, E; Jónasson, K; Laufs, J; Sigvaldason, A; Söebech, E; Stefansson, K; Thorsteinsson, L, 2004)
"These findings suggest that bronchial asthma with mucoid impactions is among several pathogeneses that cause increased levels of CEA in serum and BALF."	1.32	[Concentrations of carcinoembryonic antigen in serum and bronchoalveolar lavage fluid of asthmatic patients with mucoid impaction]. ( Fukui, Y; Harada, T; Hizawa, N; Kikuchi, E; Maeda, Y; Nagai, K; Nishimura, M; Suko, N; Takahashi, D, 2004)
"Plastic bronchitis was observed in 44 years old man, who expectorated white, branching, bronchial casts for three months."	1.31	[Plastic bronchitis and mucoid impaction--uncommon disease syndromes with expectoration mucus plugs]. ( Bestry, I; Pirozynski, M; Płodziszewska, M; Rowińska-Zakrzewska, E; Sledziewska, J; Wiatr, E; Załeska, J; Załeska, M, 2001)
"We encountered a patient with bronchial asthma and mucoid impaction who presented with a high concentration of carcinoembryonic antigen (CEA) in serum."	1.30	[A patient with bronchial asthma and mucoid impaction who presented with a high concentration of carcinoembryonic antigen in serum]. ( Araki, M; Hiraki, S; Matsuo, K; Watanabe, Y, 1997)
"Eosinophilia was abolished, yet mucus staining in the epithelium persisted."	1.30	Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. ( Bottomly, K; Brombacher, F; Cohn, L; Homer, RJ; MacLeod, H; Mohrs, M, 1999)
"These results show that in bronchial asthma patients, mucus hypersecretion is more often observed clinically in those with SDIA and in women, and that this hypersecretion is closely correlated with BAL eosinophilia, which is a feature of the pathophysiological changes that occur in the airways of these patients."	1.29	Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in adult patients with bronchial asthma. ( Kimura, I; Kitani, H; Mifune, T; Mitsunobu, F; Okazaki, M; Tanizaki, Y, 1993)
"Fifty patients with bronchial asthma were divided into four groups according to the amount of expectoration per day: 0-24, 25-49, 50-99 and 100+ ml/day."	1.29	[Clinical features of bronchial asthma with mucus hypersecretion]. ( Kimura, I; Kitani, H; Mifune, T; Mitsunobu, F; Okazaki, M; Soda, R; Tada, S; Takahashi, K; Tanizaki, Y, 1993)
"Eosinophilia was associated with asthma and with phlegm production."	1.28	Asthma, hay fever, and phlegm production associated with distinct patterns of allergy skin test reactivity, eosinophilia, and serum IgE levels. The Normative Aging Study. ( O'Connor, GT; Sparrow, D; Tollerud, DJ; Weiss, ST, 1991)
"Cough was due to one condition in 73%, two in 23%, and three in 3%."	1.28	Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. ( Curley, FJ; French, CL; Irwin, RS, 1990)

Research

Studies (705)

Authors

Clinical Trials (38)

Trial Overview

Trial Outcomes

Mean Duration of Worsening Asthma Symptoms Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection

Timeframe	Studies, this research(%)	All Research%
pre-1990	211 (29.93)	18.7374
1990's	60 (8.51)	18.2507
2000's	171 (24.26)	29.6817
2010's	191 (27.09)	24.3611
2020's	72 (10.21)	2.80

Authors	Studies
Ma, Q	1
Tong, H	1
Jing, J	1
Dhar, R	1
SCHILLER, IW	1
MICHELSON, AL	1
FRIEDMAN, S	1
KARLIN, H	1
LEVY, DL	1
UNGER, DL	3
TOWNLEY, RG	1
BRONSTEIN, SB	1
LEVIN, SJ	2
SCHERER, RA	1
GHORY, JE	1
BERNSTEIN, IL	1
KREINDLER, L	1
AUSDENMOORE, RW	1
HEISEN, AJ	1
HEISEN, A	1
DAMRAU, F	1
GROVER, FW	1
WEISNAGEL, J	1
Nguyen, TT	1
Fallon, B	1
Winfield, HN	1
Unger, L	2
Temple, DE	2
Falliers, CJ	1
Cato, AE	1
Harris, JR	1
Brandon, BM	1
Stolley, PD	1
West, SK	1
Swartz, D	1
Rumrill, R	1
Heilborn, H	1
Odeblad, E	1
Kokkola, K	1
Vaara, J	1
Wójcicki, J	1
Samochowiec, L	1
Szwed, G	1
Sawiński, J	1
Fiedelman, W	1
Martens, J	1
Block, SH	1
Parrillo, OJ	1
Humoller, FL	1
von Wichert, P	1
Brechter, C	1
Blumstein, CG	1
Bürgi, H	2
Radha, TC	1
Venkatachalam, CG	1
Viswanathan, R	1
Taylor, WF	1
Siegel, SC	2
Busser, RJ	1
Strick, L	1
Heimlich, EM	1
Pedersen, AT	1
Batsakis, JG	1
Vanselow, NA	1
McLean, JA	1
Nam, HH	1
Lee, JH	1
Ryu, SM	1
Lee, S	2
Yang, S	1
Noh, P	1
Moon, BC	1
Kim, JS	5
Seo, YS	1
Lim, JO	1
Lee, SJ	2
Kim, WI	2
Pak, SW	2
Moon, C	1
Shin, IS	13
Heo, JD	1
Ko, JW	5
Kim, JC	6
Kumar, SS	1
Binu, A	1
Devan, AR	1
Nath, LR	1
Ma, J	2
Liu, MX	1
Chen, LC	1
Shen, JJ	1
Kuo, ML	1
Tajiri, T	1
Matsumoto, H	2
Jinnai, M	1
Kanemitsu, Y	1
Nagasaki, T	1
Iwata, T	1
Inoue, H	3
Nakaji, H	1
Oguma, T	2
Ito, I	1
Niimi, A	1
Kubczak, M	1
Michlewska, S	1
Bryszewska, M	1
Aigner, A	1
Ionov, M	1
Mummy, DG	1
Dunican, EM	5
Carey, KJ	1
Evans, MD	1
Elicker, BM	3
Newell, JD	3
Gierada, DS	3
Nagle, SK	2
Schiebler, ML	4
Sorkness, RL	1
Jarjour, NN	3
Denlinger, LC	2
Fahy, JV	14
Fain, SB	3
Hearn, AP	1
Mak, MS	1
Budaj, I	1
Qurashi, N	1
Snell, O	1
Dhariwal, J	1
Nanzer, AM	1
Jackson, DJ	1
Headland, SE	1
Dengler, HS	1
Xu, D	2
Teng, G	1
Everett, C	1
Ratsimandresy, RA	1
Yan, D	1
Kang, J	2
Ganeshan, K	1
Nazarova, EV	1
Gierke, S	1
Wedeles, CJ	1
Guidi, R	1
DePianto, DJ	1
Morshead, KB	1
Huynh, A	1
Mills, J	1
Flanagan, S	1
Hambro, S	1
Nunez, V	1
Klementowicz, JE	1
Shi, Y	3
Wang, J	5
Bevers, J	1
Ramirez-Carrozzi, V	1
Pappu, R	1
Abbas, A	1
Vander Heiden, J	1
Choy, DF	1
Yadav, R	1
Modrusan, Z	1
Panettieri, RA	1
Koziol-White, C	1
Jester, WF	1
Jenkins, BJ	1
Cao, Y	1
Clarke, C	1
Austin, C	1
Lafkas, D	1
Xu, M	1
Wolters, PJ	1
Arron, JR	1
West, NR	1
Wilson, MS	2
Wu, D	2
Jiang, W	1
Liu, C	4
Liu, L	3
Li, F	1
Ma, X	1
Pan, L	1
Qu, X	1
Liu, H	3
Qin, X	1
Xiang, Y	1
Tang, M	2
Henry, T	1
Huang, BK	1
Peters, MC	3
Castro, M	3
Hoffman, EA	3
Ash, SY	1
Choi, J	1
Hall, C	1
Phillips, BR	2
Mauger, DT	2
Israel, E	2
Phipatanakul, W	1
Levy, BD	2
Wenzel, SE	2
Bleecker, ER	2
Woodruff, PG	4
Ousingsawat, J	3
Centeio, R	3
Cabrita, I	3
Talbi, K	2
Zimmer, O	1
Graf, M	1
Göpferich, A	1
Schreiber, R	4
Kunzelmann, K	4
Svenningsen, S	6
Nair, P	6
McIntosh, MJ	2
Kooner, HK	2
Eddy, RL	3
Jeimy, S	1
Licskai, C	2
Mackenzie, CA	2
Yamashita, C	2
Parraga, G	3
Sajuthi, SP	2
Everman, JL	2
Jackson, ND	2
Saef, B	1
Rios, CL	2
Moore, CM	1
Mak, ACY	1
Eng, C	2
Fairbanks-Mahnke, A	1
Salazar, S	1
Elhawary, J	1
Huntsman, S	1
Medina, V	1
Nickerson, DA	1
Germer, S	1
Zody, MC	1
Abecasis, G	1
Kang, HM	1
Rice, KM	1
Kumar, R	1
Zaitlen, NA	1
Oh, S	1
Rodríguez-Santana, J	2
Burchard, EG	2
Seibold, MA	2
Mann, TS	1
Larcombe, AN	1
Wang, KCW	1
Shamsuddin, D	1
Landwehr, KR	1
Noble, PB	1
Henry, PJ	1
Wang, Z	3
Xin, L	1
Zhang, W	7
Tao, X	1
Xia, J	1
Zeng, P	1
Wang, H	4
Xie, Y	1
Wang, C	2
Cheng, Y	1
Li, J	4
Zhang, X	3
Zhang, P	1
Chen, S	1
Yu, H	2
Wu, H	2
Wuniqiemu, T	2
Teng, F	2
Qin, J	2
Lv, Y	1
Nabijan, M	1
Luo, Q	1
Zhou, Y	2
Cui, J	2
Tang, W	2
Zhu, X	2
Wang, S	8
Abduwaki, M	1
Nurahmat, M	1
Wei, Y	2
Dong, JC	1
Eddie, AM	1
Chen, KW	1
Schenkel, LB	1
Swinger, KK	1
Molina, JR	1
Kunii, K	1
Raybuck, AL	1
Keilhack, H	1
Gibson-Corley, KN	1
Niepel, M	1
Peebles, RS	2
Boothby, MR	1
Cho, SH	1
Peng, JQ	1
Wang, P	3
Gao, YX	1
DU, Y	1
Chen, XX	1
Yu, QY	1
Ren, JG	1
Liu, JX	1
Virmani, T	1
Kumar, G	1
Virmani, R	1
Sharma, A	2
Pathak, K	1
Zhi, W	1
Jiang, S	2
Xu, Z	3
An, Y	1
Chen, J	1
Li, Y	5
Liu, Y	6
Zhang, H	2
Pieper, M	1
Schulz-Hildebrandt, H	1
Schmudde, I	1
Quell, KM	1
Laumonnier, Y	1
Hüttmann, G	1
König, P	1
Sun, Y	3
Miao, X	1
Zhu, L	1
Liu, J	3
Lin, Y	2
Xiang, G	1
Wu, X	1
Wang, X	8
Ni, Z	1
Li, S	1
Chang, C	1
Wu, JW	1
Peng, YS	1
Liu, KX	1
Tran, C	1
Singh, GV	1
Haider, E	3
Boylan, C	3
Venegas, C	2
Riaz, S	1
Al Duwaiki, S	1
Yehia, M	1
Ho, T	1
Kirby, M	2
Aegerter, H	2
Lambrecht, BN	4
Lu, X	1
Tan, ZX	1
Wang, WJ	1
Zhan, P	1
Wang, Y	7
Fu, L	1
Gao, L	1
Zhao, H	2
Xu, DX	1
Oguma, A	3
Shimizu, K	3
Kimura, H	3
Tanabe, N	3
Sato, S	3
Yokota, I	3
Takimoto-Sato, M	3
Matsumoto-Sasaki, M	3
Abe, Y	3
Takei, N	3
Goudarzi, H	3
Suzuki, M	3
Makita, H	3
Hirai, T	4
Nishimura, M	4
Konno, S	3
Pangeni, R	1
Meng, T	1
Poudel, S	1
Sharma, D	1
Hutsell, H	1
Rubin, BK	10
Longest, W	1
Hindle, M	1
Xu, Q	1
Wilson, A	1
Serajeddini, H	1
Bhalla, A	1
Nomura, N	1
Sunadome, H	1
Wei, L	2
Hongping, H	1
Chufang, L	1
Cuomu, M	1
Jintao, L	1
Kaiyin, C	1
Lvyi, C	1
Weiwu, C	1
Zuguang, Y	1
Nanshan, Z	1
Sakai, N	1
Koya, T	1
Murai, Y	1
Tsubokawa, F	1
Tanaka, K	1
Naramoto, S	1
Aoki, A	1
Shima, K	1
Kimura, Y	1
Watanabe, S	1
Hasegawa, T	1
Kikuchi, T	1
Tsuchiya, N	1
Hahn, A	1
Fain, S	1
Denlinger, L	1
Jarjour, N	1
Chan, R	1
Duraikannu, C	1
Thouseef, MJ	1
Lipworth, B	1
Hou, Y	1
Zheng, S	1
Zou, F	1
Wang, D	3
Da, H	1
Fan, X	1
He, J	1
Li, H	3
Sun, X	1
Kjarsgaard, M	1
Konyer, N	1
Friedlander, Y	1
Nasir, N	1
Wang, BH	1
Tang, LL	1
Sun, XH	1
Zhang, Q	2
Liu, CY	1
Zhang, XN	1
Yu, KY	1
Yang, Y	2
Hu, J	2
Shi, XL	1
Lee, IS	1
Yang, YG	1
Kim, T	1
Benedetto, R	2
Lu, C	2
Zhang, B	2
Xu, T	2
Bai, B	1
Xiao, Z	2
Wu, L	2
Liang, G	2
Zhang, Y	10
Dai, Y	3
Yao, N	1
Fu, X	1
Ding, M	1
Pang, Y	1
Liu, D	1
Ren, Y	1
Guo, M	1
Tasena, H	3
Boudewijn, IM	1
Faiz, A	2
Timens, W	1
Hylkema, MN	1
Berg, M	1
Ten Hacken, NHT	2
Brandsma, CA	1
Heijink, IH	2
van den Berge, M	3
Okauchi, S	1
Yamada, H	1
Satoh, H	2
Koch, S	1
Knipfer, L	1
Kölle, J	1
Mirzakhani, H	1
Graser, A	1
Zimmermann, T	1
Kiefer, A	1
Melichar, VO	1
Rascher, W	1
Papadopoulos, NG	1
Rieker, RJ	1
Raby, BA	1
Weiss, ST	2
Wirtz, S	1
Finotto, S	1
Ge, X	1
Dai, W	1
Chen, H	1
Ying, S	2
Kwon, HJ	4
Seo, CS	6
Choi, SJ	1
Shin, NR	7

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC[NCT06152653]	Phase 4	20 participants (Anticipated)	Interventional	2023-11-21	Recruiting
A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI[NCT03733535]		29 participants (Actual)	Interventional	2022-03-01	Active, not recruiting
The Effect of Immunostimulation With Polyvalent Mechanical Bacterial Lysate on Changes in the Concentration of iNKT Cells in Children With Allergic Rhinitis.[NCT04802616]	Phase 3	80 participants (Actual)	Interventional	2021-03-22	Completed
The Effect Of Polivalent Mechanical Bacterial Lysate On The Clinical Course Of Grass Pollen-Induced Allergic Rhinitis In Children[NCT04270552]	Phase 3	76 participants (Actual)	Interventional	2018-04-22	Completed
The Effect of Polyvalent Mechanical Bacterial Lysate on the Reduction of Nasal Staphylococcus Aureus Carriage in Children With Pollen Allergic Rhinitis[NCT04637425]	Phase 3	70 participants (Actual)	Interventional	2018-04-22	Completed
Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915]		107 participants (Actual)	Observational	2012-11-28	Completed
Clinical and Molecular Phenotypes of Severe Asthma[NCT01718197]		151 participants (Actual)	Observational	2012-11-30	Completed
A Two-arm, Placebo-controlled, Randomized Clinical Trial to Evaluate the Effect of Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma[NCT05280418]	Phase 3	30 participants (Anticipated)	Interventional	2022-11-08	Recruiting
Severe Asthma Research Program[NCT01606826]		1,100 participants (Anticipated)	Observational	2012-10-31	Active, not recruiting
Severe Asthma Research Program[NCT01759186]		300 participants (Anticipated)	Observational	2012-12-31	Active, not recruiting
Severe Asthma Research Program (SARP)-Washington University[NCT01716494]		121 participants (Actual)	Observational	2012-10-31	Active, not recruiting
The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.[NCT01750411]		87 participants (Actual)	Observational	2012-12-31	Completed
ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III[NCT01761630]		126 participants (Actual)	Observational	2012-12-31	Completed
"Validation of a Questionnaire to Assess Bronchial Mucus Hypersecretion in Asthmatic Patients. Questionnaire T-sec (Secretion Test)."[NCT05546645]		100 participants (Anticipated)	Observational	2023-10-01	Recruiting
A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04784754]	Phase 2	0 participants (Actual)	Interventional	2021-04-01	Withdrawn (stopped due to lack of subject enrollment)
A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04474483]	Phase 2	8 participants (Actual)	Interventional	2020-11-06	Terminated (stopped due to difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects)
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513458]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-09-30	Withdrawn (stopped due to [The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.)
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513471]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-08-09	Withdrawn (stopped due to The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.)
A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.[NCT01192178]	Phase 4	339 participants (Actual)	Interventional	2010-08-31	Completed
Evaluating the Effects of Curcumin in Moderate to Severe Asthmatics[NCT04353310]	Phase 2	0 participants (Actual)	Interventional	2021-09-30	Withdrawn (stopped due to No funding)
Role of Cough Assist Device in Mechanically Ventilated Patients in Respiratory Intensive Care Unit : Assiut University Experience[NCT05480371]		200 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190]	Phase 1	6 participants (Actual)	Interventional	2017-06-05	Terminated (stopped due to Phase II funding not available)
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]		29 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Evidence that the dose is insufficient.)
Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial.[NCT05342558]	Phase 4	133 participants (Actual)	Interventional	2017-09-19	Completed
Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management[NCT04628962]		250 participants (Anticipated)	Observational	2022-02-01	Recruiting
Phenotyping Disease Severity in Asthma: Molecular Investigations of Corticosteroid[NCT05078021]		60 participants (Anticipated)	Observational	2022-04-21	Recruiting
A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)[NCT01097694]	Phase 2	176 participants (Actual)	Interventional	2010-11-30	Completed
Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype[NCT02075151]		50 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Clinical Trial of NAC in Asthma[NCT02605824]	Phase 4	1 participants (Actual)	Interventional	2016-03-31	Terminated (stopped due to The study was closed after we determined that this albuterol/NAC regimen may be associated with excessive bronchoconstriction.)
The Effect of NAC on Lung Function and CT Mucus Score[NCT03822637]	Phase 4	30 participants (Anticipated)	Interventional	2019-02-20	Recruiting
Inpatient Clinical Trial of NAC[NCT03581084]	Phase 4	1 participants (Actual)	Interventional	2018-07-06	Terminated (stopped due to The study was redesigned to be conducted in an outpatient setting.)
A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recurrent Osteosarcoma and Ewing's Sarcoma in Patients With Lung Metastases[NCT04183062]	Phase 2	10 participants (Anticipated)	Interventional	2019-10-04	Active, not recruiting
Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD- A Multicenter Randomized Controlled Double-blind Study[NCT04061161]	Phase 4	50 participants (Anticipated)	Interventional	2019-08-19	Recruiting
: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.[NCT00669331]	Phase 3	485 participants (Actual)	Interventional	2009-11-30	Completed
Clinical Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis[NCT03727347]		50 participants (Actual)	Interventional	2018-10-16	Completed
Effect of Exposure to Allergens and Air Pollution on Lung Function and Immunity[NCT01792232]		18 participants (Actual)	Interventional	2011-10-31	Completed
[NCT00005284]		0 participants	Observational	1985-01-31	Completed
Assessment of Radio(Chemo)Therapy-related Dysphagia in Head and Neck Cancer Patients Based on Cough-related Acoustic Features[NCT05865756]		40 participants (Anticipated)	Interventional	2021-04-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A worsening asthma day is one on which any of the following occurred: rescue albuterol use above baseline, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study medication, asthma symptom scores >=3, nighttime awakenings, unscheduled health care visits, or missed school due to asthma. The duration of worsening asthma is the number of consecutive worsening asthma days after the date of a URTS score of 2 (moderate) or 3 (severe) or collection of a mucus sample containing RV (whichever occurred first). Each span of consecutive days is a participant interval. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Mean Percentage of Asthma-control Days

Intervention	Days per participant interval (Mean)
FSC DISKUS 100/50 mcg BID	4.1
FP DISKUS 100 mcg BID	4.0

An asthma-control day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than double-blind study treatment, asthma symptom score >0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, or school absenteeism due to asthma. The percentage of asthma-control days = the number (No.) of asthma-control days divided by the No. of days of treatment exposure, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Mean Percentage of Episode-free (EF) Days

Intervention	Percentage of days (Mean)
FSC DISKUS 100/50 mcg BID	48.3
FP DISKUS 100 mcg BID	49.7

An EF day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study treatment, asthma symptom score >0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, school absenteeism due to asthma, or morning peak expiratory flow (measure of maximum airflow) <80% of baseline. Percentage of EF days=No. of EF days divided by No. of days of treatment exposure, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Mean Percentage of Rescue-free Days

Intervention	Percentage of days (Mean)
FSC DISKUS 100/50 mcg BID	42.4
FP DISKUS 100 mcg BID	44.5

A rescue-free day was defined as a day during the Peak Viral Period on which no puffs of rescue medication were recorded. Percentage of rescue-free days was defined as the number of days during the Peak Viral Period on which no puffs of rescue medication were recorded, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Mean Percentage of Symptom-free Days

Intervention	Percentage of days (Mean)
FSC DISKUS 100/50 mcg BID	92.1
FP DISKUS 100 mcg BID	91.7

A symptom-free day was defined as a day during the Peak Viral Period on which the asthma symptom score was zero. The daily asthma symptom score (measured during the day and the previous night) was reported on a 6-point scale (ranging from 0=no symptoms to 5=severe symptoms). Percentage of symptom-free days was defined as the number of days during the Peak Viral Period on which the asthma symptom score=0, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Number of Asthma Exacerbations Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection During the Peak Viral Period

Intervention	Percentage of days (Mean)
FSC DISKUS 100/50 mcg BID	90.1
FP DISKUS 100 mcg BID	91.1

Each participant (with assistance from the parent/legal guardian as needed) was instructed to keep an electronic diary (eDiary) with record of daily URTS symptoms that included: runny nose, sneezing, nasal congestion, and sore throat. Based on the best-described aggregate URTS during the previous 24 hours, participants rated symptoms as: 0 = Not present; 1 = Mild, clearly present; 2 = Moderately severe, uncomfortable; and 3 = Severe, interfering with sleep or activity. Mucus samples were collected and analyzed for RVwhen the eDiary alerted for moderate/severe URTS. (NCT01192178)
Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Total Number of Asthma Exacerbations Reported During the Treatment Period

Intervention	Number of asthma exacerbations (Number)
FSC DISKUS 100/50 mcg BID	5
FP DISKUS 100 mcg BID	7

An asthma exacerbation was defined as deterioration of asthma that required the use of outpatient oral/parenteral corticosteroids (tablets, suspensions, or injection) or an urgent care, hospitalization, or emergency room (ER) visit due to asthma that required oral/parenteral corticosteroids. Two exacerbations (out of a total of 51) were excluded: (1) one exacerbation occurred within 7 days of the resolution of an earlier one, and, per protocol, was combined with the previous exacerbation; and (2) one exacerbation occurred post treatment. (NCT01192178)
Timeframe: From Baseline (Week 1) until the end of treatment (up to Week 16)

Mean Asthma Symptom Scores, as an Indicator of Severity, Associated With the Presence of Moderate or Severe Upper Respiratory Tract Symptoms (URTS) or a Confirmed Rhinovirus (RV) Infection at Baseline and During the Peak Viral Period

Intervention	Number of asthma exacerbations (Number)
FSC DISKUS 100/50 mcg BID	24
FP DISKUS 100 mcg BID	25

Participants recorded their asthma symptom score over the previous 24 hours (during the day and the previous night) using the following 6-point scale: 0=No symptoms; 1=Symptoms for 1 short period; 2=Symptoms for >=2 short periods; 3=Symptoms for most of the day/previous night that did not affect normal daily activities; 4=Symptoms for most of the day/previous night that affected normal daily activities; 5=Symptoms so severe that participant could not perform normal daily activities. The Baseline mean asthma symptom score was calculated as the average score over 7 days prior to Week 1, Visit 2. (NCT01192178)
Timeframe: Baseline (Week 1) and Peak Viral Period ([period during which the greatest number of viral infections is expected] from 30 August 2010 through the end of the treatment period [up to Week 16])

Number of Participants With Dose Limiting Toxicity

Intervention	Scores on a scale (Mean)
	Baseline, n=105, 104	Peak Viral Period, n=106, 104
FP DISKUS 100 mcg BID	0.2	0.4
FSC DISKUS 100/50 mcg BID	0.2	0.5

Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks

Diastolic Blood Pressure

Heart Rate

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Intervention	Participants (Count of Participants)
Phase Ib	0

Intervention	mmHg (Mean)
Treatment	-0.6
Control	1

Intervention	beats per minute (Mean)
Treatment	-1.4
Control	4

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Intervention	units on a scale (Least Squares Mean)
Treatment	-1.3
Control	-0.25

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Intervention	units on a scale (Mean)
Treatment	12.5
Control	17.7

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Intervention	units on a scale (Least Squares Mean)
Treatment	-44.03
Control	-6.07

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Systolic Blood Pressure

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Intervention	units on a scale (Least Squares Mean)
Treatment	-27.3
Control	0.4

Intervention	mmHg (Mean)
Treatment	-4.5
Control	-6.6

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	64.3	35.0	90.0	16.7

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Airway Wall Area

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	31.8	24.14	72.00	8.00

Change in airway wall area as assessed by computerized tomography (CT) (NCT01097694)
Timeframe: 6 months after start of treatment

Airway Wall Thickness

Intervention	% of area (Mean)
Imatinib Mesylate	0.0002
Placebo	0.0002

Change in airway wall thickness as assessed by computerized tomography (CT) (NCT01097694)
Timeframe: 6 months after start of treatment

Asthma Control Questionnaire (ACQ)

Intervention	% of airway (Mean)
Imatinib Mesylate	-0.0040
Placebo	-0.0027

Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5. (NCT01097694)
Timeframe: 6 months after start of treatment

Asthma Quality of Life Questionnaire (AQLQ)

Intervention	units on a scale (Mean)
Imatinib Mesylate	-0.62
Placebo	-0.49

Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5. (NCT01097694)
Timeframe: 6 months after start of treatment

Asthma Symptom Utility Index (ASUI)

Intervention	units on a scale (Mean)
Imatinib Mesylate	0.55
Placebo	0.25

Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09. (NCT01097694)
Timeframe: 6 months after start of treatment

BAL Eosinophil %

Intervention	units on a scale (Mean)
Imatinib Mesylate	0.07
Placebo	0.05

Change in BAL eosinophil percentage (NCT01097694)
Timeframe: 6 months after start of treatment

BAL Neutrophil %

Intervention	% eosinophils (Mean)
Imatinib Mesylate	2.55
Placebo	-2.63

Change in BAL neutrophil percentage from baseline (NCT01097694)
Timeframe: 6 months after start of treatment

Blood Eosinophils

Intervention	% neutrophils (Mean)
Imatinib Mesylate	-0.8
Placebo	-0.4

Change in blood eosinophil count (NCT01097694)
Timeframe: 6 months after start of treatment

Bronchoalveolar Lavage (BAL) Fluid Tryptase Level

Intervention	eosinophils per microliter (Mean)
Imatinib Mesylate	-10.2
Placebo	-2.6

Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo (NCT01097694)
Timeframe: 6 months after start of treatment

Bronchoalveolar Lavage (BAL) PGD2

Intervention	ng/mL (Mean)
Imatinib Mesylate	-0.74
Placebo	0.43

Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment

Bronchoalveolar Lavage Cysteinyl Leukotrienes

Intervention	pg/mL (Mean)
Imatinib Mesylate	12.2
Placebo	-4.2

Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment

Bronchoalveolar Lavage Histamine

Intervention	pg/mL (Mean)
Imatinib Mesylate	3.0
Placebo	6.5

Change in bronchoalveolar lavage histamine levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment

Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %

Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline

Intervention	nM (Mean)
Imatinib Mesylate	2.1
Placebo	-1.1

Intervention	% of predicted (Mean)
Imatinib Mesylate	0.01
Placebo	-0.08

"Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.~PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1)." (NCT01097694)
Timeframe: Over 6 months from beginning of treatment

Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells

Intervention	Log2 Ratio (Mean)
Imatinib Mesylate	1.73
Placebo	1.07

Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment

Endobronchial Biopsy Total Tryptase-positive Mast Cells

Intervention	mast cells per mm2 (Mean)
Imatinib Mesylate	-102.7
Placebo	-79.2

Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months (NCT01097694)
Timeframe: 6 months after start of treatment

Evening Peak Flow

Intervention	mast cells per mm2 (Mean)
Imatinib Mesylate	-54.2
Placebo	-32.3

Change in patient-reported evening peak flow measurement (L/s) (NCT01097694)
Timeframe: 6 months after start of treatment

FEV1 in Liters

Intervention	L/second (Mean)
Imatinib Mesylate	8.3
Placebo	-8.2

Change in FEV1 in treatment group compared to placebo group (NCT01097694)
Timeframe: 6 months after start of treatment

FEV1%

Intervention	L (Mean)
Imatinib Mesylate	0.046
Placebo	0

Change in FEV1% of predicted (NCT01097694)
Timeframe: 6 months after start of treatment

Fractional Exhaled Nitric Oxide (FeNO)

Intervention	% of predicted (Mean)
Imatinib Mesylate	2.3
Placebo	0.78

Change in Fractional Exhaled Nitric Oxide Measurement (ppb) (NCT01097694)
Timeframe: 6 months after start of treatment

Morning Peak Flow Measurement

Intervention	parts per billion (Mean)
Imatinib Mesylate	7.89
Placebo	-5.92

Change in patient-reported morning peak flow measurement (L/s) (NCT01097694)
Timeframe: 6 months after start of treatment

Number of Asthma Exacerbations

Intervention	L/second (Mean)
Imatinib Mesylate	7.3
Placebo	-6.4

Number of asthma exacerbations experienced from randomization to study completion. (NCT01097694)
Timeframe: Up to 24 weeks

Serum Total Tryptase

Intervention	events (Number)
Imatinib Mesylate	16
Placebo	20

Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment (NCT01097694)
Timeframe: 6 months after start of treatment

Urinary Leukotriene E4

Intervention	ng/ml (Mean)
Imatinib Mesylate	-2.02
Placebo	-0.56

Change in urinary leukotriene E4 levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment

Urinary Prostaglandin D2

Intervention	ng/mg Creatinine (Mean)
Imatinib Mesylate	0.07
Placebo	0.01

Change in urinary Prostaglandin D2 levels from baseline (NCT01097694)
Timeframe: 6 months after start of treatment

Forced Expiratory Volume in One Second (FEV1) Measurement

Intervention	ng/mg Creatinine (Mean)
Imatinib Mesylate	-0.30
Placebo	0.39

Post-treatment FEV1 is reported. FEV1 is measured via spirometry. (NCT03581084)
Timeframe: end of the one week treatment period

• (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations

Intervention	liters (Number)
N-acetylcysteine	0.86

Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times. (NCT00669331)
Timeframe: 52 weeks

Antibiotic Use Prescribed for Treated Pulmonary Exacerbations

Intervention	hospitalisations/year (Mean)
Mannitol	0.12
Control	0.20

Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event. (NCT00669331)
Timeframe: 52 weeks

Duration of Graded Exacerbations

Intervention	events/year (Number)
Mannitol	1.9
Control	2.1

Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable (NCT00669331)
Timeframe: 52 weeks

Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)

Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)

Lung Function - Change in FEV1/FVC

FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC*100 (NCT00669331)
Timeframe: 52 weeks

Lung Function - Change in FVC (Forced Vital Capacity)

Safety Profile - Hematology

hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline. (NCT00669331)
Timeframe: 52 weeks

Safety Profile - Sputum Microbiology

sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit (NCT00669331)
Timeframe: 52 weeks

Time to First Graded Exacerbation

Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation. (NCT00669331)
Timeframe: 52 weeks

Daytime Sleepiness Scores

Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks (NCT00669331)
Timeframe: 52 weeks

Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score

The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit. (NCT00669331)
Timeframe: 52 weeks

Rate of Graded Pulmonary Exacerbations

A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of >20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year (NCT00669331)
Timeframe: 52 weeks

Safety Profile - Clinical Chemistry

Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline. (NCT00669331)
Timeframe: 52 weeks

Sputum Volume

24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52 (NCT00669331)
Timeframe: 52 weeks

Change in Reflective Total Nasal Symptom Score (rTNSS)

"Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value.~The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit" (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure

Change in rTNSS Over Time

"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity.~The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded." (NCT03727347)
Timeframe: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.

Percentage of Participants With Treatment Related Adverse Events (Safety)

"Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure.~This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure." (NCT03727347)
Timeframe: At or following the study procedure, and up to the final study visit at 1 year.

rTNSS Responder Rate

"The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected." (NCT03727347)
Timeframe: Comparison of scores at Baseline and 12 weeks post procedure

Change in rTNSS Individual Nasal Symptom Component Scores Over Time

"Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity.~Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity." (NCT03727347)
Timeframe: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure

Response on Aerin Quality-of-Life (QOL) Assessment Items

"This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative.~Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response." (NCT03727347)
Timeframe: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.

Intervention	units on a scale (Mean)
	Baseline	Week 6	Week 16	Week 28	Week 40	Week 52
Control	6.89	6.87	6.50	6.57	6.33	6.34
Mannitol	7.23	6.07	6.21	6.05	6.32	6.09

Intervention	GPE events per year (Number)
	Raw rate	Rate from negative binomial model
Control	2.10	1.84
Mannitol	1.95	1.69

Intervention	participants (Number)
	Subjects with Clin sig liver funtion tests at wk52	Subjects with clin sig urea/electrolyte test wk52
Control	0	0
Mannitol	2	3

Intervention	score on a scale (Mean)
Treatment Group - Baseline	8.5
Treatment Group - 2 Week Data	4.8
Treatment Group - 4 Week Data	3.6
Treatment Group - 12 Week Data	3.4
Treatment Group - 26 Week Data	3.3
Treatment Group - 52 Week Data	3.6

Intervention	score on a scale (Mean)
	Rhinorrhea	Nasal Congestion	Nasal Itching	Sneezing
Treatment Group - 12 Week Data	1.0	1.1	0.5	0.9
Treatment Group - 2 Week Data	1.6	1.5	0.7	1.0
Treatment Group - 26 Week Data	0.9	1.1	0.5	0.8
Treatment Group - 4 Week Data	1.2	1.1	0.4	0.8
Treatment Group - 52 Week Data	1.1	1.2	0.5	0.8
Treatment Group - Baseline	2.5	2.5	1.7	1.9

Intervention	Participants (Count of Participants)
	Section 1, Item 1: Difficulty falling asleep72500892		Section 1, Item 1: Difficulty falling asleep72500885	Section 1, Item 1: Difficulty falling asleep72500891	Section 1, Item 1: Difficulty falling asleep72500893	Section 1, Item 2: Good sleep throughout the night72500885	Section 1, Item 2: Good sleep throughout the night72500891	Section 1, Item 2: Good sleep throughout the night72500892	Section 1, Item 2: Good sleep throughout the night72500893	Section 1, Item 3: Feeling fatigued during the day72500885	Section 1, Item 3: Feeling fatigued during the day72500891	Section 1, Item 3: Feeling fatigued during the day72500892	Section 1, Item 3: Feeling fatigued during the day72500893	Section 1, Item 4: Feelings of frustration/restlessness/irritability72500885	Section 1, Item 4: Feelings of frustration/restlessness/irritability72500891	Section 1, Item 4: Feelings of frustration/restlessness/irritability72500892	Section 1, Item 4: Feelings of frustration/restlessness/irritability72500893	Section 1, Item 5: Feelings of embarrassment or self-consciousness72500885	Section 1, Item 5: Feelings of embarrassment or self-consciousness72500891	Section 1, Item 5: Feelings of embarrassment or self-consciousness72500892	Section 1, Item 5: Feelings of embarrassment or self-consciousness72500893	Section 1, Item 6: Having a good sense of overall well-being72500885	Section 1, Item 6: Having a good sense of overall well-being72500891	Section 1, Item 6: Having a good sense of overall well-being72500892	Section 1, Item 6: Having a good sense of overall well-being72500893	Section 2, Item 1: Oral medications72500885	Section 2, Item 1: Oral medications72500891	Section 2, Item 1: Oral medications72500892	Section 2, Item 1: Oral medications72500893	Section 2, Item 2: Nasal sprays72500885	Section 2, Item 2: Nasal sprays72500891	Section 2, Item 2: Nasal sprays72500892	Section 2, Item 2: Nasal sprays72500893	Section 2, Item 3: Nasal breathing strips72500885	Section 2, Item 3: Nasal breathing strips72500891	Section 2, Item 3: Nasal breathing strips72500892	Section 2, Item 3: Nasal breathing strips72500893
	Positive (favorable) response	Neutral or Negative response
Treatment Group - 12 Week Data	23
Treatment Group - 26 Week Data	26
Treatment Group - 12 Week Data	25
Treatment Group - Baseline	11
Treatment Group - 26 Week Data	28
Treatment Group - 52 Week Data	22
Treatment Group - Baseline	35
Treatment Group - 26 Week Data	20
Treatment Group - 52 Week Data	25
Treatment Group - Baseline	3
Treatment Group - 12 Week Data	17
Treatment Group - 26 Week Data	14
Treatment Group - Baseline	43
Treatment Group - 12 Week Data	31
Treatment Group - 26 Week Data	34
Treatment Group - Baseline	7
Treatment Group - 12 Week Data	30
Treatment Group - 52 Week Data	29
Treatment Group - Baseline	39
Treatment Group - 12 Week Data	18
Treatment Group - 52 Week Data	18
Treatment Group - 12 Week Data	38
Treatment Group - 52 Week Data	33
Treatment Group - 12 Week Data	10
Treatment Group - 52 Week Data	14
Treatment Group - Baseline	24
Treatment Group - 12 Week Data	36
Treatment Group - 26 Week Data	38
Treatment Group - 52 Week Data	40
Treatment Group - Baseline	22
Treatment Group - 12 Week Data	12
Treatment Group - 26 Week Data	10
Treatment Group - 52 Week Data	7
Treatment Group - Baseline	10
Treatment Group - 12 Week Data	20
Treatment Group - 26 Week Data	17
Treatment Group - 52 Week Data	19
Treatment Group - Baseline	36
Treatment Group - 12 Week Data	28
Treatment Group - 26 Week Data	31
Treatment Group - 52 Week Data	28
Treatment Group - Baseline	9
Treatment Group - 52 Week Data	20
Treatment Group - Baseline	37
Treatment Group - 12 Week Data	24
Treatment Group - 26 Week Data	22
Treatment Group - 52 Week Data	27
Treatment Group - Baseline	41
Treatment Group - 12 Week Data	45
Treatment Group - 26 Week Data	46
Treatment Group - 52 Week Data	45
Treatment Group - Baseline	5
Treatment Group - 12 Week Data	3
Treatment Group - 26 Week Data	2
Treatment Group - 52 Week Data	2

Article	Year
Controlled assessment of oral bronchodilators for asthmatic children. The Journal of international medical research, 1978, Volume: 6, Issue:4 Topics: Administration, Oral; Adolescent; Asthma; Barbiturates; Bronchodilator Agents; Child; Clinical Trial	1978
Effect of bromhexine and guaiphenesine on clinical state, ventilatory capacity and sputum viscosity in chronic asthma. Scandinavian journal of respiratory diseases, 1976, Volume: 57, Issue:2 Topics: Airway Resistance; Asthma; Bromhexine; Chronic Disease; Clinical Trials as Topic; Female; Guaifenesi	1976
Clinical evaluation of terbutaline and glyceryl guaiacolate in chronic obstructive lung disease. Current therapeutic research, clinical and experimental, 1976, Volume: 19, Issue:3 Topics: Adult; Aged; Asthma; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Guaifenesin; Hum	1976
The use of Duopect as expectorant--antitussive agent. Archivum immunologiae et therapiae experimentalis, 1975, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aged; Asthma; Bronchiectasis; Bronchitis; Chronic Disease; Clinical Trials as Top	1975
Guaiphenesin and iodide. Drug and therapeutics bulletin, 1985, Aug-12, Volume: 23, Issue:16 Topics: Asthma; Clinical Trials as Topic; Double-Blind Method; Guaifenesin; Humans; Iodides; Lung Diseases;	1985
Clinical trial with terbutaline and guajacol. Scandinavian journal of respiratory diseases, 1973, Volume: 54, Issue:2 Topics: Adult; Aged; Asthma; Bronchodilator Agents; Butylamines; Clinical Trials as Topic; Cough; Drug Combi	1973
Changes in the fibre system and viscosity of the sputum of bronchitis during treatment with bromhexine and guaiphenesin (guaiacol glyceryl ether). Scandinavian journal of respiratory diseases. Supplementum, 1974, Volume: 90 Topics: Adult; Aged; Asthma; Bromhexine; Bronchitis; Clinical Trials as Topic; Depression, Chemical; DNA; Fe	1974
Double-blind evaluation of an anti-asthmatic agent. Annals of allergy, 1967, Volume: 25, Issue:10 Topics: Adolescent; Adult; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Female; Guaifenes	1967
A controlled evaluation of oral theophylline in asthmatic children. Annals of allergy, 1968, Volume: 26, Issue:10 Topics: Asthma; Capsules; Child; Clinical Trials as Topic; Drug Synergism; Epinephrine; Female; Guaifenesin;	1968
Asthma Control, Airway Mucus, and Chest, 2022, Volume: 162, Issue:3 Topics: Airway Management; Airway Obstruction; Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Ast	2022
Effects of Dupilumab on Mucus Plugging and Ventilation Defects in Patients with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Trial. American journal of respiratory and critical care medicine, 2023, 11-01, Volume: 208, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Asthma; Double-Blind Method; Humans; Injections, Subcutaneous; Mu	2023
Randomised study of the immunomodulatory effects of azithromycin in severely asthmatic horses. The Veterinary record, 2019, 08-03, Volume: 185, Issue:5 Topics: Airway Remodeling; Animals; Asthma; Azithromycin; Cross-Over Studies; Female; Horse Diseases; Horses	2019
The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: descriptive, prospective, clinical trial. The clinical respiratory journal, 2014, Volume: 8, Issue:3 Topics: Adolescent; Asthma; Bronchitis; Child; Child, Preschool; Chronic Disease; Cough; Female; Gastroesoph	2014
The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: a randomized study. Respiratory medicine, 2015, Volume: 109, Issue:10 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Asthma; Bronchodilato	2015
Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. The Journal of allergy and clinical immunology, 1984, Volume: 74, Issue:1 Topics: Adolescent; Adult; Asthma; Clinical Trials as Topic; Complement System Proteins; Cromolyn Sodium; Fe	1984
Cough and expectoration: general discussion. European journal of respiratory diseases. Supplement, 1980, Volume: 110 Topics: Acute Disease; Asthma; Biological Transport; Bronchitis; Chronic Disease; Cilia; Clinical Trials as	1980
Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: role of slow reacting substance of anaphylaxis. The American review of respiratory disease, 1981, Volume: 124, Issue:2 Topics: Adolescent; Adult; Airway Resistance; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Chromone	1981
The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. The European respiratory journal, 1997, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Asthma; Breathing Exercises; Combined Modality Therapy; Community Health Se	1997
Substance P and its receptor neurokinin 1 expression in asthmatic airways. The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:4 Topics: Adult; Anti-Bacterial Agents; Asthma; Biopsy; Bronchi; Epithelium; Female; Forced Expiratory Volume;	2000
The protective effect of ketotifen in bronchial asthma. The Journal of international medical research, 1978, Volume: 6, Issue:2 Topics: Adolescent; Adult; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Dyspnea;	1978
A double blind trial of a 2% solution of sodium cromoglycate in perennial rhinitis. Clinical allergy, 1975, Volume: 5, Issue:2 Topics: Adolescent; Adult; Allergens; Asthma; Child; Clinical Trials as Topic; Cromolyn Sodium; Desensitizat	1975
The effect of unproductive coughing/FET on regional mucus movement in the human lungs. Respiratory medicine, 1991, Volume: 85 Suppl A Topics: Aerosols; Aged; Asthma; Bronchitis; Cough; Female; Humans; Lung; Male; Middle Aged; Mucociliary Clea	1991
Theophylline and mucociliary clearance. Chest, 1987, Volume: 92, Issue:1 Suppl Topics: Aminophylline; Animals; Asthma; Bronchitis; Cilia; Clinical Trials as Topic; Dogs; Humans; Lung Dise	1987
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (London, England), 1969, Nov-22, Volume: 2, Issue:7630 Topics: Adult; Airway Resistance; Aniline Compounds; Asthma; Chronic Disease; Clinical Trials as Topic; Fema	1969
A new mucolytic, bromhexine ("bisolvon"). A double-blind study. The Medical journal of Australia, 1971, May-01, Volume: 1, Issue:18 Topics: Aniline Compounds; Asthma; Bronchiectasis; Bronchitis; Clinical Trials as Topic; Expectorants; Femal	1971
The acute action of urea on ventilatory function in patients with asthma. The Medical journal of Australia, 1967, Jul-08, Volume: 2, Issue:2 Topics: Adult; Aerosols; Aged; Asthma; Clinical Trials as Topic; Female; Humans; Isoproterenol; Male; Middle	1967

Authors	Studies
Ma, Q	1
Tong, H	1
Jing, J	1
Dhar, R	1
SCHILLER, IW	1
MICHELSON, AL	1
FRIEDMAN, S	1
KARLIN, H	1
LEVY, DL	1
UNGER, DL	3
TOWNLEY, RG	1
BRONSTEIN, SB	1
LEVIN, SJ	2
SCHERER, RA	1
GHORY, JE	1
BERNSTEIN, IL	1
KREINDLER, L	1
AUSDENMOORE, RW	1
HEISEN, AJ	1
HEISEN, A	1
DAMRAU, F	1
GROVER, FW	1
WEISNAGEL, J	1
Nguyen, TT	1
Fallon, B	1
Winfield, HN	1
Unger, L	2
Temple, DE	2
Falliers, CJ	1
Cato, AE	1
Harris, JR	1
Brandon, BM	1
Stolley, PD	1
West, SK	1
Swartz, D	1
Rumrill, R	1
Heilborn, H	1
Odeblad, E	1
Kokkola, K	1
Vaara, J	1

guaifenesin and Asthma

Research Excerpts

Research

Studies (705)

Authors

Clinical Trials (38)

Trial Overview

Trial Outcomes

Mean Duration of Worsening Asthma Symptoms Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection

Mean Percentage of Asthma-control Days

Mean Percentage of Episode-free (EF) Days

Mean Percentage of Rescue-free Days

Mean Percentage of Symptom-free Days

Number of Asthma Exacerbations Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection During the Peak Viral Period

Total Number of Asthma Exacerbations Reported During the Treatment Period

Mean Asthma Symptom Scores, as an Indicator of Severity, Associated With the Presence of Moderate or Severe Upper Respiratory Tract Symptoms (URTS) or a Confirmed Rhinovirus (RV) Infection at Baseline and During the Peak Viral Period

Number of Participants With Dose Limiting Toxicity

Diastolic Blood Pressure

Heart Rate

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Systolic Blood Pressure

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Airway Wall Area

Airway Wall Thickness

Asthma Control Questionnaire (ACQ)

Asthma Quality of Life Questionnaire (AQLQ)

Asthma Symptom Utility Index (ASUI)

BAL Eosinophil %

BAL Neutrophil %

Blood Eosinophils

Bronchoalveolar Lavage (BAL) Fluid Tryptase Level

Bronchoalveolar Lavage (BAL) PGD2

Bronchoalveolar Lavage Cysteinyl Leukotrienes

Bronchoalveolar Lavage Histamine

Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %

Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline

Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells

Endobronchial Biopsy Total Tryptase-positive Mast Cells

Evening Peak Flow

FEV1 in Liters

FEV1%

Fractional Exhaled Nitric Oxide (FeNO)

Morning Peak Flow Measurement

Number of Asthma Exacerbations

Serum Total Tryptase

Urinary Leukotriene E4

Urinary Prostaglandin D2

Forced Expiratory Volume in One Second (FEV1) Measurement

• (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations

Antibiotic Use Prescribed for Treated Pulmonary Exacerbations

Duration of Graded Exacerbations

Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)

Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)

Lung Function - Change in FEV1/FVC

Lung Function - Change in FVC (Forced Vital Capacity)

Safety Profile - Hematology

Safety Profile - Sputum Microbiology

Time to First Graded Exacerbation

Daytime Sleepiness Scores

Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score

Rate of Graded Pulmonary Exacerbations

Safety Profile - Clinical Chemistry

Sputum Volume

Change in Reflective Total Nasal Symptom Score (rTNSS)

Change in rTNSS Over Time

Percentage of Participants With Treatment Related Adverse Events (Safety)

rTNSS Responder Rate

Change in rTNSS Individual Nasal Symptom Component Scores Over Time

Response on Aerin Quality-of-Life (QOL) Assessment Items

Reviews

Trials

Other Studies